STAT activation in malignancies: Roles in tumor progression and in the generation of antineoplastic effects of IFNs

Journal of Interferon and Cytokine Research

Volumn 33, Issue 4, 2013, Pages 181-188

  Wang, Ben X ^a,b   Platanias, Leonidas C ^c,d   Fish, Eleanor N ^a,b  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c NORTHWESTERN UNIVERSITY   (United States)

^d NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; CAVEOLIN 1; GAMMA INTERFERON; INTERFERON; INTERLEUKIN 21; INTERLEUKIN 6; STAT PROTEIN; STAT1 PROTEIN; STAT3 PROTEIN; STAT5 PROTEIN; STAT5A PROTEIN; STAT5B PROTEIN; STAT6 PROTEIN;

ANTINEOPLASTIC ACTIVITY; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CARCINOGENESIS; GENE ACTIVATION; HUMAN; PRIORITY JOURNAL; PROTO ONCOGENE; REVIEW;

APOPTOSIS; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; DISEASE PROGRESSION; ENZYME ACTIVATION; HUMANS; INTERFERONS; NEOPLASMS; SIGNAL TRANSDUCTION; STAT TRANSCRIPTION FACTORS;

EID: 84876155664     PISSN: 10799907     EISSN: 15577465     Source Type: Journal    
DOI: 10.1089/jir.2012.0154     Document Type: Review

References (119)

1. Akira S. 1999. Functional roles of STAT family proteins: lessons from knockout mice. Stem Cells 17(3):138-146.
2. Akira S. 2000. Roles of STAT3 defined by tissue-specific gene targeting. Oncogene 19(21):2607-2611.
3. Alas S, Bonavida B. 2001. Rituximab inactivates signal transducer and activation of transcription 3 (STAT3) activity in B-non-Hodgkin's lymphoma through inhibition of the interleukin 10 autocrine/paracrine loop and results in downregulation of Bcl-2 and sensitization to cytotoxic drugs. Cancer Res 61(13):5137-5144.
4. Alas S, Emmanouilides C, Bonavida B. 2001. Inhibition of interleukin 10 by rituximab results in down-regulation of bcl-2 and sensitization of B-cell non-Hodgkin's lymphoma to apoptosis. Clin Cancer Res 7(3):709-723.
5. Abdulghani J, Gu L, Dagvadorj A, Lutz J, Leiby B, Bonuccelli G, Lisanti MP, Zellweger T, Alanen K, Mirtti T, Visakorpi T, Bubendorf L, Nevalainen MT. 2008. Stat3 promotes metastatic progression of prostate cancer. Am J Pathol 172(6):1717-1728.
6. Arora A, Scholar EM. 2005. Role of tyrosine kinase inhibitors in cancer therapy. J Pharmacol Exp Ther 315(3):971-979.
7. Arredondo J, Chernyavsky AI, Jolkovsky DL, Pinkerton KE, Grando SA. 2006. Receptor-mediated tobacco toxicity: cooperation of the Ras/Raf-1/MEK1/ERK and JAK-2/STAT-3 pathways downstream of alpha7 nicotinic receptor in oral keratinocytes. FASEB J 20(12):2093-2101.
8. Aziz MH, Manoharan HT, Verma AK. 2007. Protein kinase C epsilon, which sensitizes skin to sun's UV radiation-induced cutaneous damage and development of squamous cell carcinomas, associates with Stat3. Cancer Res 67(3):1385-1394.
9. Barbieri I, Pensa S, Pannellini T, Quaglino E, Maritano D, Demaria M, Voster A, Turkson J, Cavallo F, Watson CJ, Provero P, Musiani P, Poli V. 2010. Constitutively active Stat3 enhances neu-mediated migration and metastasis in mammary tumors via upregulation of Cten. Cancer Res 70(6):2558-2567.
10. Barton BE, Karras JG, Murphy TF, Barton A, Huang HF. 2004. Signal transducer and activator of transcription 3 (STAT3) activation in prostate cancer: direct STAT3 inhibition induces apoptosis in prostate cancer lines. Mol Cancer Ther 3(1):11-20.
11. Benekli M, Baumann H, Wetzler M. 2009. Targeting signal transducer and activator of transcription signaling pathway in leukemias. J Clin Oncol 27(26):4422-4432.
12. Benekli M, Xia Z, Donohue KA, Ford LA, Pixley LA, Baer MR, Baumann H, Wetzler M. 2002. Constitutive activity of signal transducer and activator of transcription 3 protein in acute myeloid leukemia blasts is associated with short disease-free survival. Blood 99(1):252-257.
13. Bewry NN, Nair RR, Emmons MF, Boulware D, Pinilla-Ibarz J, Hazlehurst LA. 2008. Stat3 contributes to resistance toward BCR-ABL inhibitors in a bone marrow microenvironment model of drug resistance. Mol Cancer Ther 7(10):3169-3175.
14. Bronte-Tinkew DM, Terebiznik M, Franco A, Ang M, Ahn D, Mimuro H, Sasakawa C, Ropeleski MJ, Peek RM, Jr., Jones NL. 2009. Helicobacter pylori cytotoxin-associated gene A activates the signal transducer and activator of transcription 3 pathway in vitro and in vivo. Cancer Res 69(2):632-639.
15. Bruns HA, Kaplan MH. 2006. The role of constitutively active Stat6 in leukemia and lymphoma. Crit Rev Oncol Hematol 57(3):245-253.
16. Buettner R, Mora LB, Jove R. 2002. Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. Clin Cancer Res 8(4):945-954.
17. Calo V, Migliavacca M, Bazan V, Macaluso M, Buscemi M, Gebbia N, Russo A. 2003. STAT proteins: from normal control of cellular events to tumorigenesis. J Cell Physiol 197(2): 157-168.
18. Chan SR, Vermi W, Luo J, Lucini L, Rickert C, Fowler AM, Lonardi S, Arthur C, Young LJ, Levy DE, Welch MJ, Cardiff RD, Schreiber RD. 2012. STAT1-deficient mice spontaneously develop estrogen receptor a-positive luminal mammary carcinomas. Breast Cancer Res 14(1):R16.
19. Chen HL, Gabrilovich D, Tampe R, Girgis KR, Nadaf S, Carbone DP. 1996. A functionally defective allele of TAP1 results in loss of MHC class I antigen presentation in a human lung cancer. Nat Genet 13(2):210-213.
20. Chen X, Vinkemeier U, Zhao Y, Jeruzalmi D, Darnell JE, Jr., Kuriyan J. 1998. Crystal structure of a tyrosine phosphorylated STAT-1 dimer bound to DNA. Cell 93(5):827-839.
21. Cheon H, Stark GR. 2009. Unphosphorylated STAT1 prolongs the expression of interferon-induced immune regulatory genes. Proc Natl Acad Sci U S A 106(23):9373-9378.
22. Chiu WT, Lee HT, Huang FJ, Aldape KD, Yao J, Steeg PS, Chou CY, Lu Z, Xie K, Huang S. 2011. Caveolin-1 upregulation mediates suppression of primary breast tumor growth and brain metastases by stat3 inhibition. Cancer Res 71(14):4932- 4943.
23. Connett JM, Hunt SR, Hickerson SM, Wu SJ, Doherty GM. 2003. Localization of IFN-gamma-activated Stat1 and IFN regulatory factors 1 and 2 in breast cancer cells. J Interferon Cytokine Res 23(11):621-630.
24. Coppola D, Parikh V, Boulware D, Blanck G. 2009. Substantially reduced expression of PIAS1 is associated with colon cancer development. J Cancer Res Clin Oncol 135(9):1287-1291.
25. Corvinus FM, Orth C, Moriggl R, Tsareva SA, Wagner S, Pfitzner EB, Baus D, Kaufmann R, Huber LA, Zatloukal K, Beug H, Ohlschlager P, Schutz A, Halbhuber KJ, Friedrich K. 2005. Persistent STAT3 activation in colon cancer is associated with enhanced cell proliferation and tumor growth. Neoplasia 7(6):545-555.
26. Das S, Roth CP, Wasson LM, Vishwanatha JK. 2007. Signal transducer and activator of transcription-6 (STAT6) is a constitutively expressed survival factor in human prostate cancer. Prostate 67(14):1550-1564.
27. Dauer DJ, Ferraro B, Song L, Yu B, Mora L, Buettner R, Enkemann S, Jove R, Haura EB. 2005. Stat3 regulates genes common to both wound healing and cancer. Oncogene 24(21):3397-3408.
28. Diaz N, Minton S, Cox C, Bowman T, Gritsko T, Garcia R, Eweis I, Wloch M, Livingston S, Seijo E, Cantor A, Lee JH, Beam CA, Sullivan D, Jove R, Muro-Cacho CA. 2006. Activation of stat3 in primary tumors from high-risk breast cancer patients is associated with elevated levels of activated SRC and survivin expression. Clin Cancer Res 12(1):20-28.
29. Ding BB, Yu JJ, Yu RY, Mendez LM, Shaknovich R, Zhang Y, Cattoretti G, Ye BH. 2008. Constitutively activated STAT3 promotes cell proliferation and survival in the activated B-cell subtype of diffuse large B-cell lymphomas. Blood 111(3): 1515-1523.
30. Eriksen KW, Søndergaard H, Woetmann A, Krejsgaard T, Skak K, Geisler C, Wasik MA, Odum N. 2009. The combination of IL-21 and IFN-alpha boosts STAT3 activation, cytotoxicity and experimental tumor therapy. Mol Immunol 46(5):812-820.
31. Fossey SL, Liao AT, McCleese JK, Bear MD, Lin J, Li PK, Kisseberth WC, London CA. 2009. Characterization of STAT3 activation and expression in canine and human osteosarcoma. BMC Cancer 9:81.
32. Gamero AM, Young MR, Mentor-Marcel R, Bobe G, Scarzello AJ, Wise J, Colburn NH. 2010. STAT2 contributes to promotion of colorectal and skin carcinogenesis. Cancer Prev Res (Phila) 3(4):495-504.
33. Garcia R, Bowman TL, Niu G, Yu H, Minton S, Muro-Cacho CA, Cox CE, Falcone R, Fairclough R, Parsons S, Laudano A, Gazit A, Levitzki A, Kraker A, Jove R. 2001. Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells. Oncogene 20(20):2499-2513.
34. Grandis JR, Drenning SD, Zeng Q, Watkins SC, Melhem MF, Endo S, Johnson DE, Huang L, He Y, Kim JD. 2000. Constitutive activation of Stat3 signaling abrogates apoptosis in squamous cell carcinogenesis in vivo. Proc Natl Acad Sci U S A 97(8):4227-4232.
35. Grimley PM, Fang H, Rui H, Petricoin EF 3rd, Ray S, Dong F, Fields KH, Hu R, Zoon KC, Audet S, Beeler J. 1998. Prolonged STAT1 activation related to the growth arrest of malignant lymphoma cells by interferon-alpha. Blood 91(8): 3017-3027.
36. Gritsko T, Williams A, Turkson J, Kaneko S, Bowman T, Huang M, Nam S, Eweis I, Diaz N, Sullivan D, Yoder S, Enkemann S, Eschrich S, Lee JH, Beam CA, Cheng J, Minton S, Muro-Cacho CA, Jove R. 2006. Persistent activation of stat3 signaling induces survivin gene expression and confers resistance to apoptosis in human breast cancer cells. Clin Cancer Res 12(1):11-19.
37. Gu L, Vogiatzi P, Puhr M, Dagvadorj A, Lutz J, Ryder A, Addya S, Fortina P, Cooper C, Leiby B, Dasgupta A, Hyslop T, Bubendorf L, Alanen K, Mirtti T, Nevalainen MT. 2010. Stat5 promotes metastatic behavior of human prostate cancer cells in vitro and in vivo. Endocr Relat Cancer 17(2):481-493.
38. Guo C, Yang G, Khun K, Kong X, Levy D, Lee P, Melamed J. 2009. Activation of Stat3 in renal tumors. Am J Transl Res 1(3):283-290.
39. Harir N, Pecquet C, Kerenyi M, Sonneck K, Kovacic B, Nyga R, Brevet M, Dhennin I, Gouilleux-Gruart V, Beug H, Valent P, Lassoued K, Moriggl R, Gouilleux F. 2007. Constitutive activation of Stat5 promotes its cytoplasmic localization and association with PI3-kinase in myeloid leukemias. Blood 109(4):1678-1686.
40. Ho HH, Ivashkiv LB. 2006. Role of STAT3 in type I interferon responses. Negative regulation of STAT1-dependent inflammatory gene activation. J Biol Chem 281(20):14111-14118.
41. Holtick U, Vockerodt M, Pinkert D, Schoof N, Sturzenhofecker B, Kussebi N, Lauber K, Wesselborg S, Loffler D, Horn F, Trumper L, Kube D. 2005. STAT3 is essential for Hodgkin lymphoma cell proliferation and is a target of tyrphostin AG17 which confers sensitization for apoptosis. Leukemia 19(6):936-944.
42. Hsieh FC, Cheng G, Lin J. 2005. Evaluation of potential Stat3- regulated genes in human breast cancer. Biochem Biophys Res Commun 335(2):292-299.
43. Humpolikova-Adamkova L, Kovarik J, Dusek L, Lauerova L, Boudny V, Fait V, Fojtova M, Krejci E, Kovarik A. 2009. Interferon-alpha treatment may negatively influence disease progression in melanoma patients by hyperactivation of STAT3 protein. Eur J Cancer 45(7):1315-1323.
44. Ikeda K, Kobayashi M, Seko Y, Imai N, Hirakawa M, Kawamura Y, Sezaki H, Hosaka T, Akuta N, Saitoh S, Suzuki F, Suzuki Y, Arase Y, Kumada H. 2010. Administration of interferon for two or more years decreases early stage hepatocellular carcinoma recurrence rate after radical ablation: A retrospective study of hepatitis C virus-related liver cancer. Hepatol Res 40(12):1168-1175.
45. Inamura K, Matsuzaki Y, Uematsu N, Honda A, Tanaka N, Uchida K. 2005. Rapid inhibition of MAPK signaling and antiproliferation effect via JAK/STAT signaling by interferonalpha in hepatocellular carcinoma cell lines. Biochim Biophys Acta 1745(3):401-410.
46. Jiang LJ, Zhang NN, Ding F, Li XY, Chen L, Zhang HX, Zhang W, Chen SJ, Wang ZG, Li JM, Chen Z, Zhu J. 2011. RAinducible gene-I induction augments STAT1 activation to inhibit leukemia cell proliferation. Proc Natl Acad Sci U S A 108(5):1897-1902.
47. Jing N, Sha W, Li Y, Xiong W, Tweardy DJ. 2005. Rational drug design of G-quartet DNA as anti-cancer agents. Curr Pharm Des 11(22):2841-2854.
48. Kaymaz BT, Selvi N, Gunduz C, Aktan C, Dalmizrak A, Saydam G, Kosova B. 2012. Repression of STAT3, STAT5A, and STAT5B expressions in chronic myelogenous leukemia cell line K-562 with unmodified or chemically modified siRNAs and induction of apoptosis. Ann Hematol 2012 [Epub ahead of print]. DOI: 10.1007/s00277-012-1575-2.
49. Khong T, Sharkey J, Spencer A. 2008. The effect of azacitidine on interleukin-6 signaling and nuclear factor-kappaB activation and its in vitro and in vivo activity against multiple myeloma. Haematologica 93(6):860-869.
50. Kisseleva T, Bhattacharya S, Braunstein J, Schindler CW. 2002. Signaling through the JAK/STAT pathway, recent advances and future challenges. Gene 285(1-2):1-24.
51. Klover PJ, Muller WJ, Robinson GW, Pfeiffer RM, Yamaji D, Hennighausen L. 2010. Loss of STAT1 from mouse mammary epithelium results in an increased Neu-induced tumor burden. Neoplasia 12(11):899-905.
52. Kluge A, Dabir S, Vlassenbroeck I, Eisenberg R, Dowlati A. 2011. Protein inhibitor of activated STAT3 expression in lung cancer. Mol Oncol 5(3):256-264.
53. Koskela HL, Eldfors S, Ellonen P, van Adrichem AJ, Kuusanma ki H, Andersson EI, Lagstrom S, Clemente MJ, Olson T, Jalkanen SE, Majumder MM, Almusa H, Edgren H, LepistoM, Mattila P, Guinta K, Koistinen P, Kuittinen T, Penttinen K, Parsons A, Knowles J, Saarela J, Wennerberg K, Kallioniemi O, Porkka K, Loughran TP, Jr., Heckman CA, Maciejewski JP, Mustjoki S. 2012. Somatic STAT3 mutations in large granular lymphocytic leukemia. N Engl J Med 366(20):1905-1913.
54. Kovacic B, Stoiber D, Moriggl R, Weisz E, Ott RG, Kreibich R, Levy DE, Beug H, Freissmuth M, Sexl V. 2006. STAT1 acts as a tumor promoter for leukemia development. Cancer Cell 10(1): 77-87.
55. Kovarik A, Fojtova M, Boudny V, Adamkova L, Lauerova L, Kovarik J. 2005. Interferon-gamma, but not interferon-alpha, induces SOCS 3 expression in human melanoma cell lines. Melanoma Res 15(6):481-488.
56. Landen CN, Jr., Lin YG, Armaiz Pena GN, Das PD, Arevalo JM, Kamat AA, Han LY, Jennings NB, Spannuth WA, Thaker PH, Lutgendorf SK, Savary CA, Sanguino AM, Lopez-Berestein G, Cole SW, Sood AK. 2007. Neuroendocrine modulation of signal transducer and activator of transcription-3 in ovarian cancer. Cancer Res 67(21):10389-10396.
57. Landolfo S, Guarini A, Riera L, Gariglio M, Gribaudo G, Cignetti A, Cordone I, Montefusco E, Mandelli F, Foa R. 2000. Chronic myeloid leukemia cells resistant to interferon-alpha lack STAT1 expression. Hematol J 1(1):7-14.
58. Lee SO, Lou W, Qureshi KM, Mehraein-Ghomi F, Trump DL, Gao AC. 2004. RNA interference targeting Stat3 inhibits growth and induces apoptosis of human prostate cancer cells. Prostate 60(4):303-309.
59. Leibowitz MS, Andrade Filho PA, Ferrone S, Ferris RL. 2011. Deficiency of activated STAT1 in head and neck cancer cells mediates TAP1-dependent escape from cytotoxic T lymphocytes. Cancer Immunol Immunother 60(4):525-535.
60. Lian JP, Word B, Taylor S, Hammons GJ, Lyn-Cook BD. 2004. Modulation of the constitutive activated STAT3 transcription factor in pancreatic cancer prevention: effects of indole-3- carbinol (I3C) and genistein. Anticancer Res 24(1):133-137.
61. Lim CP, Cao X. 2006. Structure, function, and regulation of STAT proteins. Mol Biosyst 2(11):536-550.
62. Lin L, Liu A, Peng Z, Lin HJ, Li PK, Li C, Lin J. 2011. STAT3 is necessary for proliferation and survival in colon cancerinitiating cells. Cancer Res 71(23):7226-7237.
63. Liu YP, Tan YN, Wang ZL, Zeng L, Lu ZX, Li LL, Luo W, Tang M, Cao Y. 2008. Phosphorylation and nuclear translocation of STAT3 regulated by the Epstein-Barr virus latent membrane protein 1 in nasopharyngeal carcinoma. Int J Mol Med 21(2): 153-162.
64. Maher SG, Sheikh F, Scarzello AJ, Romero-Weaver AL, Baker DP, Donnelly RP, Gamero AM. 2008. IFNalpha and IFNlambda differ in their antiproliferative effects and duration of JAK/STAT signaling activity. Cancer Biol Ther 7(7):1109- 1115.
65. Malin S, McManus S, Busslinger M. 2010. STAT5 in B cell development and leukemia. Curr Opin Immunol 22(2): 168-176.
66. Mora LB, Buettner R, Seigne J, Diaz J, Ahmad N, Garcia R, Bowman T, Falcone R, Fairclough R, Cantor A, Muro-Cacho C, Livingston S, Karras J, Pow-Sang J, Jove R. 2002. Constitutive activation of Stat3 in human prostate tumors and cell lines: direct inhibition of Stat3 signaling induces apoptosis of prostate cancer cells. Cancer Res 62(22):6659-6666.
67. Nair RR, Tolentino JH, Hazlehurst LA. 2012. Role of STAT3 in Transformation and Drug Resistance in CML. Front Oncol 2:30.
68. Niu G, Wright KL, Ma Y, Wright GM, Huang M, Irby R, Briggs J, Karras J, Cress WD, Pardoll D, Jove R, Chen J, Yu H. 2005. Role of Stat3 in regulating p53 expression and function. Mol Cell Biol 25(17):7432-7440.
69. Ozawa Y, Williams AH, Estes ML, Matsushita N, Boschelli F, Jove R, List AF. 2008. Src family kinases promote AML cell survival through activation of signal transducers and activators of transcription (STAT). Leuk Res 32(6):893-903.
70. Paner GP, Silberman S, Hartman G, Micetich KC, Aranha GV, Alkan S. 2003. Analysis of signal transducer and activator of transcription 3 (STAT3) in gastrointestinal stromal tumors. Anticancer Res 23(3B):2253-2260.
71. Pedranzini L, Leitch A, Bromberg J. 2004. Stat3 is required for the development of skin cancer. J Clin Invest 114(5):619-622.
72. Pilati C, Amessou M, Bihl MP, Balabaud C, Nhieu JT, Paradis V, Nault JC, Izard T, Bioulac-Sage P, Couchy G, Poussin K, Zucman-Rossi J. 2011. Somatic mutations activating STAT3 in human inflammatory hepatocellular adenomas. J Exp Med 208(7):1359-1366.
73. Platanias LC. 2005. Mechanisms of type-I- and type-II-interferonmediated signalling. Nat Rev Immunol 5(5):375-386.
74. Punjabi AS, Carroll PA, Chen L, Lagunoff M. 2007. Persistent activation of STAT3 by latent Kaposi's sarcoma-associated herpesvirus infection of endothelial cells. J Virol 81(5):2449- 2458.
75. Radaeva S, Jaruga B, Hong F, Kim WH, Fan S, Cai H, Strom S, Liu Y, El-Assal O, Gao B. 2002. Interferon-alpha activates multiple STAT signals and down-regulates c-Met in primary human hepatocytes. Gastroenterology 122(4):1020-1034.
76. Rebouissou S, Amessou M, Couchy G, Poussin K, Imbeaud S, Pilati C, Izard T, Balabaud C, Bioulac-Sage P, Zucman-Rossi J. 2009. Frequent in-frame somatic deletions activate gp130 in inflammatory hepatocellular tumours. Nature 457(7226): 200-204.
77. Redell MS, Ruiz MJ, Alonzo TA, Gerbing RB, Tweardy DJ. 2011. Stat3 signaling in acute myeloid leukemia: ligand-dependent and -independent activation and induction of apoptosis by a novel small-molecule Stat3 inhibitor. Blood 117(21):5701-5709.
78. Reich NC, Liu L. 2006. Tracking STAT nuclear traffic. Nat Rev Immunol 6(8):602-612.
79. Scarzello AJ, Romero-Weaver AL, Maher SG, Veenstra TD, Zhou M, Qin A, Donnelly RP, Sheikh F, Gamero AM. 2007. A Mutation in the SH2 domain of STAT2 prolongs tyrosine phosphorylation of STAT1 and promotes type I IFN-induced apoptosis. Mol Biol Cell 18(7):2455-2462.
80. Schindler C, Plumlee C. 2008. Inteferons pen the JAK-STAT pathway. Semin Cell Dev Biol 19(4):311-318.
81. Schlessinger K, Levy DE. 2005. Malignant transformation but not normal cell growth depends on signal transducer and activator of transcription 3. Cancer Res 65(13):5828-5834.
82. Shen H, Lentsch AB. 2004. Progressive dysregulation of transcription factors NF-kappa B and STAT1 in prostate cancer cells causes proangiogenic production of CXC chemokines. Am J Physiol Cell Physiol 286(4):C840-C847.
83. Shukla S, Shishodia G, Mahata S, Hedau S, Pandey A, Bhambhani S, Batra S, Basir SF, Das BC, Bharti AC. 2010. Aberrant expression and constitutive activation of STAT3 in cervical carcinogenesis: implications in high-risk human papillomavirus infection. Mol Cancer 9:282.
84. Sommer VH, Clemmensen OJ, Nielsen O, Wasik M, Lovato P, Brender C, Eriksen KW, Woetmann A, Kaestel CG, Nissen MH, Ropke C, Skov S, Odum N. 2004. In vivo activation of STAT3 in cutaneous T-cell lymphoma. Evidence for an antiapoptotic function of STAT3. Leukemia 18(7):1288-1295.
85. Song L, Rawal B, Nemeth JA, Haura EB. 2011. JAK1 activates STAT3 activity in non-small-cell lung cancer cells and IL-6 neutralizing antibodies can suppress JAK1-STAT3 signaling. Mol Cancer Ther 10(3):481-494.
86. Sun WH, Pabon C, Alsayed Y, Huang PP, Jandeska S, Uddin S, Platanias LC, Rosen ST. 1998. Interferon-alpha resistance in a cutaneous T-cell lymphoma cell line is associated with lack of STAT1 expression. Blood 91(2):570-576.
87. Takeda K, Noguchi K, Shi W, Tanaka T, Matsumoto M, Yoshida N, Kishimoto T, Akira S. 1997. Targeted disruption of the mouse Stat3 gene leads to early embryonic lethality. Proc Natl Acad Sci U S A 94(8):3801-3804.
88. Tanaka T, Soriano MA, Grusby MJ. 2005. SLIM is a nuclear ubiquitin E3 ligase that negatively regulates STAT signaling. Immunity 22(6):729-736.
89. Tu B, Du L, Fan QM, Tang Z, Tang TT. 2012. STAT3 activation by IL-6 from mesenchymal stem cells promotes the proliferation and metastasis of osteosarcoma. Cancer Lett 325(1): 80-88.
90. Turkson J, Jove R. 2000. STAT proteins: novel molecular targets for cancer drug discovery. Oncogene 19(56):6613-6626.
91. Turkson J, Kim JS, Zhang S, Yuan J, Huang M, Glenn M, Haura E, Sebti S, Hamilton AD, Jove R. 2004. Novel peptidomimetic inhibitors of signal transducer and activator of transcription 3 dimerization and biological activity. Mol Cancer Ther 3(3):261-269.
92. Vitale G, Zappavigna S, Marra M, Dicitore A, Meschini S, Condello M, Arancia G, Castiglioni S, Maroni P, Bendinelli P, Piccoletti R, van Koetsveld PM, Cavagnini F, Budillon A, Abbruzzese A, Hofland LJ, Caraglia M. 2012. The PPAR-g agonist troglitazone antagonizes survival pathways induced by STAT-3 in recombinant interferon-b treated pancreatic cancer cells. Biotechnol Adv 30(1):169-184.
93. Warsch W, Kollmann K, Eckelhart E, Fajmann S, Cerny-Reiterer S, Holbl A, Gleixner KV, Dworzak M, Mayerhofer M, Hoermann G, Herrmann H, Sillaber C, Egger G, Valent P, Moriggl R, Sexl V. 2011. High STAT5 levels mediate imatinib resistance and indicate disease progression in chronic myeloid leukemia. Blood 117(12):3409-3420.
94. Weerasinghe P, Garcia GE, Zhu Q, Yuan P, Feng L, Mao L, Jing N. 2007. Inhibition of Stat3 activation and tumor growth suppression of non-small cell lung cancer by G-quartet oligonucleotides. Int J Oncol 31(1):129-136.
95. Widschwendter A, Tonko-Geymayer S, Welte T, Daxenbichler G, Marth C, Doppler W. 2002. Prognostic significance of signal transducer and activator of transcription 1 activation in breast cancer. Clin Cancer Res 8(10):3065-3074.
96. Wilop S, van Gemmeren TB, Lentjes MH, van Engeland M, Herman JG, Brummendorf TH, Jost E, Galm O. 2011. Methylation-associated dysregulation of the suppressor of cytokine signaling-3 gene in multiple myeloma. Epigenetics 6(8):1047-1052.
97. Wormald S, Hilton DJ. 2004. Inhibitors of cytokine signal transduction. J Biol Chem 279(2):821-824.
98. Xi S, Zhang Q, Dyer KF, Lerner EC, Smithgall TE, Gooding WE, Kamens J, Grandis Jr. 2003. Src kinases mediate STAT growth pathways in squamous cell carcinoma of the head and neck. J Biol Chem 278(34):31574-31583.
99. Xia Z, Sait SN, Baer MR, Barcos M, Donohue KA, Lawrence D, Ford LA, Block AM, Baumann H, Wetzler M. 2001a. Truncated STAT proteins are prevalent at relapse of acute myeloid leukemia. Leuk Res 25(6):473-482.
100. Xia Z, Salzler RR, Kunz DP, Baer MR, Kazim L, Baumann H, Wetzler M. 2001b. A novel serine-dependent proteolytic activity is responsible for truncated signal transducer and activator of transcription proteins in acute myeloid leukemia blasts. Cancer Res 61(4):1747-1753.
101. Xie TX, Huang FJ, Aldape KD, Kang SH, Liu M, Gershenwald JE, Xie K, Sawaya R, Huang S. 2006. Activation of stat3 in human melanoma promotes brain metastasis. Cancer Res 66(6):3188-3196.
102. Xiong H, Hong J, Du W, Lin YW, Ren LL, Wang YC, Su WY, Wang JL, Cui Y, Wang ZH, Fang JY. 2012. Roles of STAT3 and ZEB1 proteins in E-cadherin down-regulation and human colorectal cancer epithelial-mesenchymal transition. J Biol Chem 287(8):5819-5832.
103. Xu G, Zhang C, Zhang J. 2009. Dominant negative STAT3 suppresses the growth and invasion capability of human lung cancer cells. Mol Med Report 2(5):819-824.
104. Yamada O, Ozaki K, Furukawa T, Machida M, Wang YH, Motoji T, Mitsuishi T, Akiyama M, Yamada H, Kawauchi K, Matsuoka R. 2011. Activation of STAT5 confers imatinib resistance on leukemic cells through the transcription of TERT and MDR1. Cell Signal 23(7):1119-1127.
105. Yang J, Chatterjee-Kishore M, Staugaitis SM, Nguyen H, Schlessinger K, Levy DE, Stark GR. 2005. Novel roles of unphosphorylated STAT3 in oncogenesis and transcriptional regulation. Cancer Res 65(3):939-947.
106. Yang J, Liao X, Agarwal MK, Barnes L, Auron PE, Stark GR. 2007. Unphosphorylated STAT3 accumulates in response to IL-6 and activates transcription by binding to NFkappaB. Genes Dev 21(11):1396-1408.
107. Yang J, Stark GR. 2008. Roles of unphosphorylated STATs in signaling. Cell Res 18(4):443-451.
108. Yoneyama M, Kikuchi M, Natsukawa T, Shinobu N, Imaizumi T, Miyagishi M, Taira K, Akira S, Fujita T. 2004. The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses. Nat Immunol 5(7): 730-737.
109. Yoshida T, Hanada T, Tokuhisa T, Kosai K, Sata M, Kohara M, Yoshimura A. 2002. Activation of STAT3 by the hepatitis C virus core protein leads to cellular transformation. J Exp Med 196(5):641-653.
110. You M, Yu DH, Feng GS. 1999. Shp-2 tyrosine phosphatase functions as a negative regulator of the interferon-stimulated Jak/STAT pathway. Mol Cell Biol 19(3):2416-2424.
111. Yu H, Pardoll D, Jove R. 2009. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer 9(11):798-809.
112. Zammarchi F, de Stanchina E, Bournazou E, Supakorndej T, Martires K, Riedel E, Corben AD, Bromberg JF, Cartegni L. 2011. Antitumorigenic potential of STAT3 alternative splicing modulation. Proc Natl Acad Sci U S A 108(43):17779-17784.
113. Zhan JF, Chen LH, Yuan YW, Xie GZ, Sun AM, Liu Y, Chen ZX. 2011. STAT1 promotes radioresistance of CD44 (+) /CD24 (- / low) cells in breast cancer. Exp Biol Med (Maywood) 236(4):418-422.
114. Zhang NN, Shen SH, Jiang LJ, Zhang W, Zhang HX, Sun YP, Li XY, Huang QH, Ge BX, Chen SJ, Wang ZG, Chen Z, Zhu J. 2008. RIG-I plays a critical role in negatively regulating granulocytic proliferation. Proc Natl Acad Sci U S A 105(30):10553-10558.
115. Zhang X, Yue P, Fletcher S, Zhao W, Gunning PT, Turkson J. 2010. A novel small-molecule disrupts Stat3 SH2 domainphosphotyrosine interactions and Stat3-dependent tumor processes. Biochem Pharmacol 79(10):1398-1409.
116. Zhang X, Yue P, Page BD, Li T, Zhao W, Namanja AT, Paladino D, Zhao J, Chen Y, Gunning PT, Turkson J. 2012. Orally bioavailable small-molecule inhibitor of transcription factor Stat3 regresses human breast and lung cancer xenografts. Proc Natl Acad Sci USA 109(24):9623-9628.
117. Zhou Y, Wang S, Gobl A, Oberg K. 2001. Interferon alpha induction of Stat1 and Stat2 and their prognostic significance in carcinoid tumors. Oncology 60(4):330-338.
118. Zhu H, Wang Z, Xu Q, Zhang Y, Zhai Y, Bai J, Liu M, Hui Z, Xu N. 2012. Inhibition of STAT1 sensitizes renal cell carcinoma cells to radiotherapy and chemotherapy. Cancer Biol Ther 13(6):401-407.
119. Zimmerman MA, Rahman NT, Yang D, Lahat G, Lazar AJ, Pollock RE, Lev D, Liu K. 2012. Unphosphorylated STAT1 promotes sarcoma development through repressing expression of Fas and bad and conferring apoptotic resistance. Cancer Res 72(18):4724-4732.